Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer. (IXOGoo1)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT01129310
First received: May 21, 2010
Last updated: January 6, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: January 2018
  Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)